TKNO Research | Milton Maxwell

TKNO

Alpha Teknova, Inc.

4.6400

+0.0500+1.09%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

-/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

FY Q4 '25

Q&A details investments, ramps

2/25/26Feb 25, 2026

Q&A fleshed out the $2 million commercial push into sequencing, spatial genomics, and cancer screening via field hires with ties to existing customers, branding, and private labeling. Custom biopharma, 25% of revenue, faces a 3-4 quarter lag from biotech funding upticks—not baked into 2026 guidance yet. Therapies show 30x spend ramps from Phase I to commercial, 10x from late-stage to launch; average revenue per customer dips from early-stage adds. FDA timeline shortcuts offer tailwinds. EBITDA positivity targeted end-2027 at $52-$57 million run-rate. Management stayed measured on 2026 acceleration. Watch biopharma funding persistence.

Key Stats

Market Cap

248.38M

P/E (TTM)

Basic EPS (TTM)

-0.33

Dividend Yield

Recent Filings

10-K

FY2025 results

3/2/26Mar 2, 2026

Alpha Teknova posted FY2025 revenue of $40.5M, up 7.4% y/y from $37.7M in 2024, with Lab Essentials at $31.0M (7.5% growth) and Clinical Solutions at $7.7M (7.8% up), fueled by more customers despite softer pricing; gross margins leaped to 33.2% from 19.2% (or 26.5% adjusted), thanks to manufacturing efficiencies after 2024's inventory writedowns. Operating loss narrowed to $17.0M from $26.1M on cost cuts, yet net loss hit $17.3M versus $26.7M prior year. Q4 momentum showed in 95% retention for high-value clients (85% revenue) and 79% custom RUO shipped under three weeks. Cash at $5.9M plus $15.4M short-term investments funds ops amid $13.2M debt; covenants met. Customer funding swings threaten demand.

8-K

Teknova beats on revenue, margins

2/26/26Feb 26, 2026

Teknova reported Q4 and full-year 2025 revenue of $10.0M and $40.5M, up 8% and 7% year-over-year, with gross margins surging to 32.5% and 33.2% from prior lows. Clinical Solutions jumped 47% in Q4. Guides 2026 revenue to $42-44M; cash burn shrinks.

10-Q

Q3 FY2025 results

11/7/25Nov 7, 2025

Teknova posted Q3 revenue of $10.5M, up 9.2% y/y from $9.6M, with gross profit leaping to $3.2M (30.7% margin) from near-zero after prior inventory writedowns. Operating loss narrowed to $4.0M from $7.4M y/y, while nine-month revenue hit $30.5M (+7.2% y/y) and operating loss shrank to $12.4M from $20.5M. Cash from operations improved to $8.2M used versus $11.5M prior; free cash flow not disclosed in the 10-Q. Debt stands at $13.1M net under a $28.2M facility (maturing 2030, Term SOFR+6.45%) with $5.0M revolver availability tied to receivables; $22.1M in cash and short-term investments tops the $8.0M covenant. Lab Essentials drove 80% of sales. Customers remain sensitive to product defects.

8-K

Q3 revenue grows 9%

11/6/25Nov 6, 2025

Alpha Teknova reported third-quarter 2025 revenue of $10.5 million, up 9% from $9.6 million last year, marking five straight quarters of growth amid biotech funding woes. Lab Essentials surged 16% to $8.3 million, offsetting a 13% dip in Clinical Solutions to $1.7 million; gross margin hit 30.7% versus 0.9%, boosted by prior-year inventory charges. Net loss narrowed to $4.3 million from $7.6 million. The company holds $22.1 million in cash and investments against $13.2 million debt. It reaffirms 2025 revenue guidance of $39-42 million. Adjusted EBITDA improved sharply.

10-Q

Q2 FY2025 results

8/8/25Aug 8, 2025

Alpha Teknova posted solid Q2 revenue of $10.3M, up 7.0% y/y from $9.6M, fueled by 31.6% growth in Clinical Solutions while Lab Essentials ticked up 2.0%; gross margin leaped to 38.7% from 29.2% on manufacturing efficiencies. Operating loss narrowed to $3.4M from $5.1M y/y, thanks to 10.1% lower G&A spend, though net loss of $3.6M exceeded operating by $0.2M due to interest expense. YTD revenue climbed 6.2% to $20.1M, with operating loss shrinking 36.2% to $8.4M and diluted EPS improving to -$0.15 from -$0.33 on 53.4M shares. Cash and equivalents stood at $3.3M plus $20.7M in short-term investments, backing $13.0M long-term debt under a March 2025 facility maturing 2030 with $5.0M revolver availability and $39.0M minimum revenue covenant for 2025. Free cash flow not disclosed in the 10-Q. Yet competition from advanced technologies looms large.

About

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

CEO

Mr. Stephen Gunstream

IPO

6/25/2021

Website

https://www.teknova.com

Employees

173

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic